535 related articles for article (PubMed ID: 15780431)
1. What do we know about the secretion and degradation of incretin hormones?
Deacon CF
Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
[TBL] [Abstract][Full Text] [Related]
2. Circulation and degradation of GIP and GLP-1.
Deacon CF
Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum.
Hansen L; Hartmann B; Mineo H; Holst JJ
Regul Pept; 2004 Apr; 118(1-2):11-8. PubMed ID: 14759551
[TBL] [Abstract][Full Text] [Related]
4. The biology of incretin hormones.
Drucker DJ
Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
[TBL] [Abstract][Full Text] [Related]
5. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
6. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.
Toft-Nielsen M; Madsbad S; Holst JJ
Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105
[TBL] [Abstract][Full Text] [Related]
7. The physiological role of GLP-1 in human: incretin, ileal brake or more?
Schirra J; Göke B
Regul Pept; 2005 Jun; 128(2):109-15. PubMed ID: 15780430
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
9. Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach.
Lippl F; Kircher F; Erdmann J; Allescher HD; Schusdziarra V
Regul Pept; 2004 Jun; 119(1-2):93-8. PubMed ID: 15093702
[TBL] [Abstract][Full Text] [Related]
10. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
11. Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
Carr RD; Larsen MO; Winzell MS; Jelic K; Lindgren O; Deacon CF; Ahrén B
Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E779-84. PubMed ID: 18612044
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
[TBL] [Abstract][Full Text] [Related]
13. On the physiology of GIP and GLP-1.
Holst JJ
Horm Metab Res; 2004; 36(11-12):747-54. PubMed ID: 15655703
[TBL] [Abstract][Full Text] [Related]
14. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
Mentlein R
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):443-52. PubMed ID: 19748062
[TBL] [Abstract][Full Text] [Related]
16. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
[TBL] [Abstract][Full Text] [Related]
17. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness.
Delmeire D; Flamez D; Moens K; Hinke SA; Van Schravendijk C; Pipeleers D; Schuit F
Biochem Pharmacol; 2004 Jul; 68(1):33-9. PubMed ID: 15183115
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose.
Damholt AB; Buchan AM; Kofod H
Endocrinology; 1998 Apr; 139(4):2085-91. PubMed ID: 9528997
[TBL] [Abstract][Full Text] [Related]
19. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
